PCSK9抑制剂依洛尤单抗实现极低LDL胆固醇浓度的临床疗效与安全性:FOURIER试验预设二次分析
该研究为FOURIER试验的预设二次分析,纳入25 982例随机分组患者(依洛尤单抗13 013例、安慰剂12 969例),评估4周时达到的LDL胆固醇浓度与后续心血管结局及10项预设安全性事件的关系,中位随访2·2年。结果显示,4周时LDL胆固醇浓度与主要和次要疗效复合终点风险呈高度显著的单调关系,延伸至最低第1百分位(LDL胆固醇<0·2 mmol/L;主要终点p=0·0012,次要终点p=0·0001)。反之,达到的LDL胆固醇与所有严重不良事件或其他9项预设安全性事件均无显著关联。作者认为这些数据支持对心血管疾病患者将LDL胆固醇降至远低于现行推荐的水平。
要点
- 4周时LDL胆固醇浓度与主要终点(心血管死亡、心肌梗死、卒中、冠状动脉血运重建或不稳定心绞痛复合)风险呈单调关系,延伸至<0·2 mmol/L(p=0·0012)。
- 4周时LDL胆固醇浓度与关键次要终点(心血管死亡、心肌梗死或卒中复合)风险呈单调关系,延伸至<0·2 mmol/L(p=0·0001)。
- 25 982例中2669例(10%)达到LDL胆固醇<0·5 mmol/L,8003例(31%)达到0·5至<1·3 mmol/L,3444例(13%)达到1·3至<1·8 mmol/L,7471例(29%)达到1·8至<2·6 mmol/L,4395例(17%)达到≥2·6 mmol/L。
- 达到的LDL胆固醇与所有严重不良事件或其他9项预设安全性事件均无显著关联。
- 中位2·2年随访中,极低LDL胆固醇浓度未发现安全性担忧。
适用人群与场景
- FOURIER试验随机分组的27 564例患者中,排除1025例(4%)4周时未测LDL胆固醇及557例(2%)4周访视前已发生主要终点事件或10项预设安全性事件之一,剩余25 982例(94%)纳入本分析。
- 纳入分析患者中13 013例分配至依洛尤单抗,12 969例分配至安慰剂。
研究设计与关键结果
- 研究类型:FOURIER试验的预设二次分析,纳入25 982例患者,中位随访2·2年,采用多变量模型校正与达到LDL胆固醇相关的基线因素。
- 主要终点为心血管死亡、心肌梗死、卒中、冠状动脉血运重建或不稳定心绞痛的复合终点;关键次要终点为心血管死亡、心肌梗死或卒中的复合终点。
- 4周时达到的LDL胆固醇浓度与主要终点风险呈高度显著单调关系,延伸至最低第1百分位(LDL胆固醇<0·2 mmol/L),p=0·0012。
- 4周时达到的LDL胆固醇浓度与关键次要终点风险呈高度显著单调关系,延伸至最低第1百分位(LDL胆固醇<0·2 mmol/L),p=0·0001。
- 4周时LDL胆固醇浓度分布:<0·5 mmol/L 2669例(10%)、0·5至<1·3 mmol/L 8003例(31%)、1·3至<1·8 mmol/L 3444例(13%)、1·8至<2·6 mmol/L 7471例(29%)、≥2·6 mmol/L 4395例(17%)。
- 达到的LDL胆固醇与所有严重不良事件或其他9项预设安全性事件均无显著关联。
- FOURIER试验于2013年2月8日至2015年6月5日随机分组27 564例患者。
证据类型、等级与局限
- 证据类型:随机对照试验FOURIER的预设二次分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,这些数据支持对心血管疾病患者将LDL胆固醇降至远低于现行推荐的水平。
- 中位2·2年随访中,极低LDL胆固醇浓度未发现安全性担忧。
指南或共识出处
- FOURIER试验(ClinicalTrials.gov注册号NCT01764633)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: LDL cholesterol is a well established risk factor for atherosclerotic cardiovascular disease. How much one should or safely can lower this risk factor remains debated. We aimed to explore the relationship between progressively lower LDL-cholesterol concentrations achieved at 4 weeks and clinical efficacy and safety in the FOURIER trial of evolocumab, a monoclonal antibody to proprotein convertase subtilisin-kexin type 9 (PCSK9).
METHODS: In this prespecified secondary analysis of 25 982 patients from the randomised FOURIER trial, the relationship between achieved LDL-cholesterol concentration at 4 weeks and subsequent cardiovascular outcomes (primary endpoint was the composite of cardiovascular death, myocardial infarction, stroke, coronary revascularisation, or unstable angina; key secondary endpoint was the composite of cardiovascular death, myocardial infarction, or stroke) and ten prespecified safety events of interest was examined over a median of 2·2 years of follow-up. We used multivariable modelling to adjust for baseline factors associated with achieved LDL cholesterol. This trial is registered with ClinicalTrials.gov, number NCT01764633.
FINDINGS: Between Feb 8, 2013, and June 5, 2015, 27 564 patients were randomly assigned a treatment in the FOURIER study. 1025 (4%) patients did not have an LDL cholesterol measured at 4 weeks and 557 (2%) had already had a primary endpoint event or one of the ten prespecified safety events before the week-4 visit. From the remaining 25 982 patients (94% of those randomly assigned) 13 013 were assigned evolocumab and 12 969 were assigned placebo. 2669 (10%) of 25 982 patients achieved LDL-cholesterol concentrations of less than 0·5 mmol/L, 8003 (31%) patients achieved concentrations between 0·5 and less than 1·3 mmol/L, 3444 (13%) patients achieved concentrations between 1·3 and less than 1·8 mmol/L, 7471 (29%) patients achieved concentrations between 1·8 to less than 2·6 mmol/L, and 4395 (17%) patients achieved concentrations of 2·6 mmol/L or higher. There was a highly significant monotonic relationship between low LDL-cholesterol concentrations and lower risk of the primary and secondary efficacy composite endpoints extending to the bottom first percentile (LDL-cholesterol concentrations of less than 0·2 mmol/L; p=0·0012 for the primary endpoint, p=0·0001 for the secondary endpoint). Conversely, no significant association was observed between achieved LDL cholesterol and safety outcomes, either for all serious adverse events or any of the other nine prespecified safety events.
INTERPRETATION: There was a monotonic relationship between achieved LDL cholesterol and major cardiovascular outcomes down to LDL-cholesterol concentrations of less than 0·2 mmol/L. Conversely, there were no safety concerns with very low LDL-cholesterol concentrations over a median of 2·2 years. These data support further LDL-cholesterol lowering in patients with cardiovascular disease to well below current recommendations.
参考来源
- Giugliano RP, Pedersen TR, Park JG, et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet. 2017. PMID: 28859947. doi:10.1016/S0140-6736(17)32290-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。